The Cancer Prevention and Research Institute of Texas has awarded UTMB more than $3.2 million to continue a program aimed at creating a new state resource — a trove of population research on cancer treatments and outcomes in Texas.
One of 11 multi-investigator research continuation grants recently announced by CPRIT, the UTMB award will fund the work of the organization Comparative Effectiveness Research on Cancer in Texas for two more years.
Led by Dr. James Goodwin, vice president and chief research officer at UTMB, CERCIT is a multidisciplinary consortium of investigators from UTMB, the University of Texas MD Anderson Cancer Center, Rice University and the Texas Cancer Registry.
CERCIT researchers are studying how screening for breast, colon, and prostate cancer is conducted throughout the state. They are looking at how access to care and quality of cancer care affect patient outcomes. They are investigating how long health care providers carry out surveillance of cancer survivors.
“This has been a very rich collaboration. The investigators from these institutions work well together,” said Goodwin. “Our different disciplines and skill sets create great synergy, not only in research, but also in training the next generation of cancer investigators.”
CERCIT was originally funded by CPRIT in 2010. Since then, the organization has become a major presence in Texas’s cancer research community.
One of its research projects culminated in the development of a white paper on cancer statistics among Hispanics in Texas distributed to 1,000 legislators and influential individuals and organizations in the Hispanic community nationwide. This is the first time any such research had ever been compiled and disseminated.
Over the course of its first four years, CERCIT has trained 24 new cancer researchers and published more than 80 peer-reviewed cancer studies in such high-profile journals as the Journal of the American Medical Association and the New England Journal of Medicine.